Abstract
Tumor samples of 240 patients with primary breast cancer were biochemically and immunohistochemically investigated for estrogen receptors (ER) and, in 130 of the samples, for progesterone-receptors (PgR) in order to examine reasons for discordant findings. The biochemical (DCCA) and immunohistochemical assays (ICA) yielded positivity in 71% for ER, and in 44% for PgR. Concordant ER-DCCA and ER-ICA results were obtained in 84%; two thirds of the discordant ER-findings manifested as DCCA-neg/ICA-pos. Concordance in the case of PgR amounted to 72%, and of the discordances 60% were DCCA-neg/ICA-pos. Significant association with postmenopausal status existed only for ER positivity in ICA (p=0.01), whereas ER-DCCA, PgR-DCCA and PgR-ICA were all more or less independent of the menopausal status. The frequency of discordances was independent of menopausal status. Discordance for ER-assays increased significantly near the respective cut-off point; this was not unequivocally true for PgR-assays. The correlation of tumor types of sparse cellularity, as well as prominent stroma content (‘scirrhous carcinoma’) with increased frequency of the constellation DCCA-neg/ICA-pos was of borderline significance for PgR (p=0.06), but not for ER. The percentage of discordant ER-findings, figuring as DCCA-neg/ICA-pos, was statistically significantly increased in locally advanced breast cancer (p=0.03). Fibrocystic disease in peritumoral breast tissue had no impact on receptor-assay discordance. In any case, the models derived from theoretical thought, laboratory data and singular observations can only in part explain the discordance in steroid receptor values measured with different methods.
Similar content being viewed by others
References
NIH Consensus Conference: Treatment of early-stage breast cancer. JAMA 265: 391–395, 1991
Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15: 20–25, 1988
Early Breast Cancer Trialist's Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 399: 1–15, 71–85, 1992
Andersen J, Thorpe SM, King WJ, Rose C, Christensen JB, Rasmussen BB, Poulsen HS: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid binding assays. Eur J Cancer 26: 442–449, 1990
Bezwoda WR, Esser JD, Dansey R, Kessel I, Lange M: The value of estrogen and progesterone receptor determinations in advanced breast cancer. Cancer 69: 867–872, 1991
Sears HF, Janus C, Levy W, Hopson R, Creech R: Breast cancer without axillary metastascs: Are there high risk biologic subpopulations? Cancer 50: 1820–1827, 1982
Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Br Cancer Res Treat 3: 157–163, 1983
Thorpe SM, Christensen JB, Rasmussen BB, Rose C: Short recurrence free survival associated with high estrogen receptor levels in the natural history of postmenopausal primary breast cancer. Eur J Cancer 29A: 971–977, 1993
De Mascarel I, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM: Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Appl Immunohistochem 3(4): 222–231, 1995
Stierer M, Rosen H, Weber R, Hannak H, Auerbach L, Spona J, Tüchler H: A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Br Cancer Res Treat 36: 11–21, 1995
Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr Jr GH, Krook JE, Wieand HS: Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78: 764–772, 1996
Clark GM, Harvey JM, Osborne CK, Allred DC: Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients. Proc ASCO 454: 129a, 1997
Barnes DM, Harris WH, Smith P, Milis RR, Rubens RD: Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74(9): 1445–1451, 1996
Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty Jr KS: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 49: 1052–1056, 1989
Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Prognostic value of steroid receptors after longterm follow-up of 2257 operable breast cancers. Br J Cancer 73: 1545–1551, 1996
Raemakers JMM, Beex LVAM, Koenders AJM: Disease free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow up. Br Cancer Res Treat 6: 123–130, 1985
Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. Eur J Cancer Clin Oncol 25: 1233–1240, 1989
Greene GL, Fitch FW, Jensen EV: Monoclonal antibodies to estrophilin: Probes for the study of estrogen receptors. Proc Natl Acad Sci USA 77: 157–161, 1980
Perrot-Applanat M, Logeat F, Croyer-Picard MT, Milgrom E: Immunocytochemical study of mammalian progesterone receptor using monoclonal antibodies. Endocrinology 116: 1473–1483, 1985
Kitchen PR, Stilwell RG, Henderson MA, Bennett RC, Rennie GC, Kou SJ, Georgiou T, Ayber KH: Oestrogen receptor assay of breast cancer by immunocytochemistry of fine needle aspirates. Aust NZ J Surg 61(3): 223–228, 1991
Katz RL, Patel S, Sneige N, Fritsche Jr HA, Hortobagyi GN, Ames FC, Brooks T, Ordonez NG: Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Br Cancer Res Treat 15(3): 191–203, 1990
Hurlimann J, Gebhard S, Gomez F: Estrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23: 239–248, 1993
Esteban J, Battifora H, Warsi Z, Bailey A, Bacus S: Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 4: 53–57, 1991
Parl FP, Posey YF: Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 129: 960–966, 1988
Beck TH, Pollow K, Grill HJ, Weikel W, Kreienberg R: Hormonrezeptornachweis der Mammakarzinome: Additive Informationen immunhistochemischer und histologischer Untersuchungen zum biochemischen Rezeptorassay. Tumor Diagnostik Therapie 10: 104–108, 1989
Allegra JC, Lippmann ME, Green L, Barlock A, Simon R, Thompson EB, Huff KK, Griffin W: Estrogen receptor values in patients with benign breast disease. Cancer 44: 228–231, 1979
Mohammed RH, Laktatua DJ, Hans E, Yashineh WJ: Estrogen and progesterone receptors in human breast cancer. Cancer 58: 1076–1081, 1986
EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer Clin Oncol 16: 1513–1515, 1980
Remmele W, Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie 8: 138–140, 1987
Neumann K, Rüschoff J, Horstmann A, Zwiorek L, Kalbfleisch H: Hormonrezeptorgehalt von Mammakarzinomen — Vergleich morphologischer und biochemischer Bestimmungsmethoden. Pathologie 10: 160–164, 1989
UICC (International Union against Cancer): TNM classifi cation of malignant tumors (3rd ed.). UICC, Geneva, 1979, p 4754
WHO: The World Health Organization histological typing of breast tumors (2nd ed.). Am J Clin Pathol 78: 806–816, 1982
Bloom HJG, Richardson WW: Histological grading and prognosis in breast carcinoma. Br J Cancer 11: 359–377, 1957
Fentiman IS: Risk factors for benign breast disease. In: Smallwood JA, Taylor I (eds) Benign Breast Disease. Urban & Schwarzenberg, 1990. p 129
Press MR, Schwartz AM: Prognostic markers in breast cancer: laboratory analysis of breast biopsies. United States and Canadian Academy of Pathology, San Francisco, 1994
Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor and patient characteristics in human breast cancer. J Clin Oncol 102: 1102–1109, 1984
Saez S, Martin PM, Chouvet CD: Estradiol and progesterone levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res 38: 3468–3474, 1978
Barrett-Lee PJ, Travers MT, McClelland RA, Lugmani Y, Coombes RC: Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res 47: 6653–6659, 1987
Pertschuk LP, Feldman JG, Eisenberg KB, Carter AC, Thelmo WL, Cruz WP, Thorpe SM, Christensen IBJ, Rasmussen BB, Rose C, Greene G: Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal an tibody, Relation to biochemical assay, disease free survival and clinical endocrine response. Cancer 62: 342–349, 1988
Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061, 1990
Perrot-Applanat M, Groyer-Picard MT, Lorenzo F, Jolivret A, Vu Hai MT: Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors. Cancer Res 47: 2652–2661, 1987
Helin H, Isola J, Helle M, Koivula T: Discordant results between radioligand and immunohistochemical assays for ste roid receptors in breast carcinoma. Br J Cancer 62: 109–112, 1990
Westphal HM, Mugele K, Beato M: Immunochemical characterization of wild-type and variant glucocorticoid receptors by monoclonal antibodies. EMBO J 3: 1493–1499, 1984
King WJ, DeSombre ER, Jensen EV: Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 45: 293–296, 1985
Jakesz R, Smith CA, Aitken S: Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res 44: 619–622, 1984
Horwitz KB, McGuire WL, Segaloff OH: A predictive response to endocrine therapy in human breast cancer. A hypothesis. Science 5: 428–433, 1975
Graham II ML, Smith JA, Jewett PB, Horwitz KB: Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res 52: 593–602, 1992
Markopoulos C, Berger UTA, Wilson P, Gazet JC, Coombes RC: Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J 296: 1349–1353, 1988
Khan SA, Rogexs MA, Obando JA, Tamsen A: Estrogen receptor expression of benign breast cpithelium and its association with breast cancer. Cancer Res 54: 993–997, 1994
Azzopardi J: Problems in breast pathology. In: Major Problems in Pathology. Vol. II, WB Saunders, 1987, pp 23–24
Sarrif AM, Durant JR: Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor. Cancer 48: 1215–1218, 1981
Greene GL, Sobel NB, King WJ: Immunochemical studies of estrogen receptors. J Steroid Biochem 20: 51–57, 1984
Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg BK, Carter AC, TianRong Z, Thelmo WL, Fleisher J, Greene GL: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66: 1663–1670, 1990
Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz Jr AB: Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125: 107–113, 1990
Esteban JM, Ahn C, Mehta P, Battifora H: Biological significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer patients. Am J Clin Pathol 102: 9–12, 1994
Al Saati T, Clamens S, Cohen-Knafo E, Faye JC, Prats H, Coindre JM, Wafflart J, Caveriviere L, Bayard F, Delsol G: Production of monoclonal antibodies to human oestrogen receptor protein (ER) using recombinant ER (RER). Int J Cancer 55: 651–654, 1993
Taylor CR, Shi S, Chaiwun B, Young L, Ashraf Imam S, Cote RJ: Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections. Hum Pathol 25: 263–270, 1994
Allred DC: Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol 99: 1–3, 1992
Battifora H, Mehta P, Ahn C, Esteban JM: Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. A better gold standard? Appl Immunochem 1: 36–45, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stierer, M., Rosen, H., Weber, R. et al. Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: Evaluation of discordant findings. Breast Cancer Res Treat 50, 125–134 (1998). https://doi.org/10.1023/A:1006046107249
Issue Date:
DOI: https://doi.org/10.1023/A:1006046107249